The growth of this market is majorly driven by the rising geriatric population (and the subsequent increase in the prevalence of chronic diseases), shift from volume- to value-based care, and delays in drug development (and the subsequent increase in development costs). The base year considered for the study is 2017 and the forecast period includes 2018 to 2023.

 [157 Pages Report] The global real-world evidence market is projected to reach USD 1,348.1 million by 2023, at a CAGR of 14.3%

By therapeutic area, the oncology segment held the largest market share of the real world evidence market in 2017.

Based on therapeutic area, the oncology segment accounted for the largest share of the real-world evidence market in 2017. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide.

Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991

By end user, the pharmaceutical & medical device companies segment held the largest market share of the real world evidence market in 2017.

Based on end user, the pharmaceutical & medical device companies segment accounted for the largest share of the real world evidence market. The large share of this segment can be attributed to the increasing importance of RWE studies in drug approvals, the need to prevent costly drug recalls, and the increasing need to assess drug performance in real-world settings.

Request a Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=76173991

North America dominated the market in 2017.

North America accounted for the largest share of the real world evidence market in 2017, followed by Europe and Asia Pacific. Presence of a favorable regulatory environment, high number of RWE service providers, the presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure, are the major factors responsible for the large share of North America in the global real world evidence market.

Key Market Players:

IQVIA (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), and Optum (US) held the major share of the real world evidence market and will continue to dominate the market between 2018 and 2023. Other major players operating in this market include International Business Machines Corporation (US), Cognizant (US), Oracle (US), SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US).

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

The growth of this market is majorly driven by the rising geriatric population (and the subsequent increase in the prevalence of chronic diseases), shift from volume- to value-based care, and delays in drug development (and the subsequent increase in development costs).

What the Market Looks Like?

Predicted to grow at a CAGR of 14.3 % during the forecast period, the global Real World Evidence Solutions market is estimated to reach USD 1,348.1 million by the end of 2023.

“By component, the data sets segment accounted for the largest share of the real world evidence market in 2017.”

On the basis of component, the data sets segment accounted for the largest share of the global real world evidence market. The large share can be attributed to factors such as easy availability of massive amounts of data, increasing dependence of outcome-based studies on real-world data, and rising demand for information by payers and providers regarding drug safety.

“By therapeutic area, the oncology segment held the largest market share of the real world evidence market in 2017.”

Based on therapeutic area, the oncology segment accounted for the largest share of the real-world evidence market in 2017. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide.

 Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991

Geographical growth scenario of Real World Evidence Solutions Market

North America accounted for the largest share of the real world evidence market in 2017, followed by Europe and Asia Pacific. Presence of a favorable regulatory environment, high number of RWE service providers, the presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure, are the major factors responsible for the large share of North America in the global real world evidence market.

Leading market players

The prominent players in the Real World Evidence Solutions market include IQVIA (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), Optum (US), International Business Machines Corporation (US), Cognizant (US), Oracle (US), SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US).

Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=76173991

I really wasn’t sure how I felt about this book until I was a few chapters in and then, well I loved this book!  Ware had just witnessed his grandmother being whisked off to the hospital and now his summer plans were ruined.  He didn’t want his parent’s Plan B for his summer, that is, until he found a tree.  Climbing that tree was the beginning of Ware’s own Plan B.

Ware’s parents had a goal for the summer and they immediately found an alternative plan for Ware when his grandmother could no longer care for him over the summer.  Ware didn’t want his parent’s alternative plan, and he was now, begging and bribing his parents to change their minds. In the end, nothing worked.

Plan B. Most everything looked the same as it did years ago, as the building appeared before him.  Ware knew he couldn’t live out the rest of this summer at the Rec.  This was daycare and he was now 11 ½, this place is not for him. I loved Ware’s attitude; at times, he acted older than he was yet there’s still that child within him.  Ware finds his escape during exercise class, when he spots a huge tree in the lot next door.  Believing that the tree would provide the perfect cover, he scales it.  How long can Ware hide up in the tree?

Ware had studied medieval times at school and he was becoming obsessed with castles, knights and various items from that era.  His plans at his grandmothers to build a replica were now cancelled but now sitting in this tree, Ware remembered the church that was on this lot. Shock came over him, as he noticed that the church had been destroyed and was now lying in pieces.  Ware notices a girl digging in the dirt, behind the church.  Trying to remain undetected, Ware creeps closer yet the girls spots him immediately.

Instantly, Jolene take control of the situation. She announces that this area is hers and that Ware needs to leave immediately!  I thought this was funny when I first read it.  It totally took Ware off-guard.  I wasn’t expecting Ware to fight back but he did.  He also took control.  He told Jolene that the church was his and her response…..well, she would just have to see about that. 

I liked how the two of them fit together.  Ware needed a space and the damaged church provided that for him.  Actually, it provided more than just a space for him to hang out but I’m not going to spoil the book for you.  Jolene needed the space behind the damaged church.  You might be thinking, what is Jolene doing? Well, Jolene is having some issues at home so she needs this space behind the church. They also needed each other, sometimes more than the physical space.  There are also problems because the lot has a sign on it and the sign means problems for more than just these two.  

Jolene and Ware worked hard and tried to transform the area that they were now trying to claim as their own.  I enjoyed reading about this and how they got along.  The references to the baptistery, the “do-over tub, the “sinner” tub, and the moat made this a fun book to read.

I loved how Ware alluded his mother each day when she dropped him off at the Rec.  Ware wanted to tell his mother what he was doing but he overheard her talking one day and he now knows, that he can’t. He then tries hard to be a knight and abide by the Knight’s Code that he has memorized.  I really enjoyed it when Uncle Cy and Ashley were added to the story, they were wonderful characters and I feel that they added a great deal to the story.  

What an excellent story, I really enjoyed it.  It was crazy good!  The ending gave me goosebumps as I was shedding happy tears.

“don’t ask to be normal- you’re better than that.”

The growth of this market is majorly driven by the rising geriatric population (and the subsequent increase in the prevalence of chronic diseases), shift from volume- to value-based care, and delays in drug development (and the subsequent increase in development costs).

The Real World Evidence Solutions market is projected to reach USD 1,348.1 million by 2023 from USD 689.9 million in 2018, at a CAGR of 14.3%.

+ Market Dynamics 

+ Drivers

+ Rising Geriatric Population and the Subsequent Increase in the Prevalence of Chronic Diseases
+ Shift From Volume- to Value-Based Care
+ Delays in Drug Development and the Subsequent Increase in Development Costs

Download PDF Brochure @
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991

“By component, the data sets segment accounted for the largest share of the real world evidence market in 2017”

The data sets segment accounted for the largest share of the global real world evidence market. The large share can be attributed to factors such as easy availability of massive amounts of data, increasing dependence of outcome-based studies on real-world data, and rising demand for information by payers and providers regarding drug safety.

“By therapeutic area, the oncology segment held the largest market share of the real world evidence market in 2017”

The oncology segment accounted for the largest share of the real-world evidence market in 2017. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide.

View complete press release:-
https://www.marketsandmarkets.com/PressReleases/real-world-evidence-solution.asp

Real-world evidence is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from the analysis of real-world data. Real-world data (RWD) is defined as data derived from a number of sources that are associated with outcomes in a heterogeneous patient population in real-world settings.

Market Size

The global Real World Evidence Solutions Market is projected to reach USD 1,348.1 million by 2023 from USD 689.9 million in 2018, at a CAGR of 14.3% during the forecast period. 

The growth of this market is majorly driven by the rising geriatric population (and the subsequent increase in the prevalence of chronic diseases), shift from volume- to value-based care, and delays in drug development (and the subsequent increase in development costs). The base year considered for the study is 2017 and the forecast period includes 2018 to 2023.

To know about the assumptions considered for the study download the pdf brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991

“By component, the data sets segment accounted for the largest share of the real world evidence market in 2017.”

On the basis of component, the data sets segment accounted for the largest share of the global real world evidence market. The large share can be attributed to factors such as easy availability of massive amounts of data, increasing dependence of outcome-based studies on real-world data, and rising demand for information by payers and providers regarding drug safety.

“By therapeutic area, the oncology segment held the largest market share of the real world evidence market in 2017.”

Based on therapeutic area, the oncology segment accounted for the largest share of the real-world evidence market in 2017. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide.

 Recent Developments

• In July 2017, ICON (Ireland) acquired Mapi Group (France), a patient-centered health outcomes research and commercialization company. 
• In October 2016, Quintiles Transnational Holdings (US) merged with IMS Health (US) to form IQVIA. 

For More Details, Request Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=76173991